The hidden burden of sarcopenia in inflammatory bowel disease: a strong predictor of complications

Background Sarcopenia is an emerging predictor of adverse outcomes in inflammatory bowel disease (IBD). We assessed its prevalence and prognostic impact in a prospective cohort. Methods Consecutive adults with IBD were prospectively enrolled (December 2023–August 2024). Sarcopenia was assessed using handgrip strength and bioelectrical impedance analysis (BIA) and patients were classified as non sarcopenic, with probable sarcopenia, or confirmed sarcopenia. Clinical worsening, IBD-related hospitalization, surgery, and infectious complications were prospectively assessed over 12 months. Results We enrolled 113 IBD patients: 32 (28.3%) were non-sarcopenic, 73 (64.6%) had probable sarcopenia, and 8 (7.1%) had confirmed sarcopenia. Confirmed sarcopenia was associated with lower BMI, higher CRP levels, and a higher prevalence of high nutritional risk. During follow-up, clinical worsening occurred in 46.9%, 45.2%, and 87.5% of patients, respectively (p=0.074), while IBD-related hospitalization occurred in 6.2%, 11.0%, and 62.5% (p<0.001). After adjustment for baseline clinical activity, confirmed sarcopenia remained independently associated with IBD-related hospitalization (adjusted OR [aOR] 18.30, 95% CI 3.21–141.14; p<0.001). Confirmed sarcopenia was also independently associated with infectious complications after adjustment for advanced-therapy exposure (aOR 7.40, 95% CI 1.17–54.63; p=0.034). No independent association was observed between sarcopenia and clinical worsening after adjustment for age, baseline clinical activity, BMI, and CRP. Conclusions In this prospective cohort of patients with IBD, confirmed sarcopenia was independently associated with an increased risk of IBD-related hospitalization and infectious complications over 12 months. These findings suggest that assessment of muscle strength and mass may provide clinically relevant prognostic information beyond conventional measures of disease activity and nutritional status.

Authors

Institutions

Publication Details

Journal
Frontiers in Gastroenterology
Published
2026-10-28
DOI
https://doi.org/10.3389/fgstr.2026.1960689
Primary Topic
Inflammatory Bowel Disease
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The hidden burden of sarcopenia in inflammatory bowel disease: a strong predictor of complications

Antonio Rispo, Fabrizio Pasanisi, Fabiana Castiglione, Maurizio Marra et al.
4 links
Frontiers in Gastroenterology
Inflammatory Bowel Disease
article

The hidden burden of sarcopenia in inflammatory bowel disease: a strong predictor of complications

Antonio Rispo, Fabrizio Pasanisi, Fabiana Castiglione, Maurizio Marra, Giulio Calabrese, Ersilia Nigro, Anna Testa, Aurora Daniele, Olga Maria Nardone, Alessia Dalila Guarino, Camilla Leo, Ludovica De Vito
article en

Abstract

Background Sarcopenia is an emerging predictor of adverse outcomes in inflammatory bowel disease (IBD). We assessed its prevalence and prognostic impact in a prospective cohort. Methods Consecutive adults with IBD were prospectively enrolled (December 2023–August 2024). Sarcopenia was assessed using handgrip strength and bioelectrical impedance analysis (BIA) and patients were classified as non sarcopenic, with probable sarcopenia, or confirmed sarcopenia. Clinical worsening, IBD-related hospitalization, surgery, and infectious complications were prospectively assessed over 12 months. Results We enrolled 113 IBD patients: 32 (28.3%) were non-sarcopenic, 73 (64.6%) had probable sarcopenia, and 8 (7.1%) had confirmed sarcopenia. Confirmed sarcopenia was associated with lower BMI, higher CRP levels, and a higher prevalence of high nutritional risk. During follow-up, clinical worsening occurred in 46.9%, 45.2%, and 87.5% of patients, respectively (p=0.074), while IBD-related hospitalization occurred in 6.2%, 11.0%, and 62.5% (p<0.001). After adjustment for baseline clinical activity, confirmed sarcopenia remained independently associated with IBD-related hospitalization (adjusted OR [aOR] 18.30, 95% CI 3.21–141.14; p<0.001). Confirmed sarcopenia was also independently associated with infectious complications after adjustment for advanced-therapy exposure (aOR 7.40, 95% CI 1.17–54.63; p=0.034). No independent association was observed between sarcopenia and clinical worsening after adjustment for age, baseline clinical activity, BMI, and CRP. Conclusions In this prospective cohort of patients with IBD, confirmed sarcopenia was independently associated with an increased risk of IBD-related hospitalization and infectious complications over 12 months. These findings suggest that assessment of muscle strength and mass may provide clinically relevant prognostic information beyond conventional measures of disease activity and nutritional status.

Frontiers in GastroenterologyVol. 5
Federico II University Hospital (IT), CEINGE Biotecnologie Avanzate Franco Salvatore (Italy) (IT), University of Naples Federico II (IT)
Good health and well-being
Openalex Percentile: Top 14%
Inflammatory Bowel Disease
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon